Ancora Advisors LLC Makes New $2.64 Million Investment in Zoetis Inc. $ZTS

Key Points

• Ancora Advisors acquired 36,761 Zoetis shares worth approximately $2.64 million during the second quarter. Institutional investors collectively own 92.8% of the company.
• Zoetis reported quarterly EPS of $1.87, slightly above analyst expectations, while revenue of $2.47 billion fell short of estimates and declined 0.2% year over year.
• Analyst sentiment is mixed but leans neutral: the stock has a consensus “Hold” rating and an average price target of $107.43, compared with a share price of $77.41.

Ancora Advisors LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 36,761 shares of the company's stock, valued at approximately $2,642,000.

Other hedge funds have also made changes to their positions in the company. University of Texas Texas AM Investment Management Co. purchased a new position in Zoetis during the 2nd quarter valued at about $25,000. Dunhill Financial LLC lifted its position in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company's stock worth $25,000 after purchasing an additional 296 shares during the period. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $28,000. Finally, Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.2%

Shares of ZTS stock opened at $77.41 on Thursday. The stock's fifty day moving average price is $75.66 and its 200 day moving average price is $96.12. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49. The company has a market cap of $31.99 billion, a price-to-earnings ratio of 12.75, a price-to-earnings-growth ratio of 1.80 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. During the same period last year, the business posted $1.76 earnings per share. The firm's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ZTS shares. Wall Street Zen downgraded shares of Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. UBS Group dropped their target price on Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research report on Friday, August 7th. Piper Sandler dropped their target price on Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research report on Monday, August 10th. BNP Paribas Exane cut their price target on Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. reduced their price target on Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $107.43.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source